{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:48:12Z","timestamp":1747162092405,"version":"3.40.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ijcha.2018.09.008","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T18:56:08Z","timestamp":1539197768000},"page":"69-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction"],"prefix":"10.1016","volume":"21","author":[{"given":"Shinichi","family":"Nonin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3607-8937","authenticated-orcid":false,"given":"Shinichi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asahiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2617-8945","authenticated-orcid":false,"given":"Ryoko","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sera","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2076-2796","authenticated-orcid":false,"given":"Atsushi","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1014-7447","authenticated-orcid":false,"given":"Akihisa","family":"Hanatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Yoshiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ijcha.2018.09.008_bb0005","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s10557-011-6349-x","article-title":"Phase III clinical pharmacology study of tolvaptan","volume":"25","author":"Inomata","year":"2011","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcha.2018.09.008_bb0010","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0015","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1253\/circj.CJ-66-0093","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload","volume":"78","author":"Kinugawa","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0020","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0025","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2018.09.008_bb0030","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1253\/circj.CJ-13-1255","article-title":"Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure","volume":"78","author":"Shirakabe","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0035","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ahj.2011.02.027","article-title":"Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials","volume":"161","author":"Pang","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0040","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1093\/eurheartj\/ehp253","article-title":"Effects of tolvaptan on dyspnoea relief from the EVEREST trials","volume":"30","author":"Pang","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0045","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00380-016-0872-4","article-title":"Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction","volume":"32","author":"Hanatani","year":"2017","journal-title":"Heart Vessel."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0050","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2018.09.008_bb0055","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0060","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","article-title":"Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients\u2013association between non-responders and chronic kidney disease","volume":"77","author":"Imamura","year":"2013","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0065","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1253\/circj.CJ-14-0244","article-title":"Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure","volume":"78","author":"Imamura","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1536\/ihj.15-297","article-title":"Tolvaptan prolongs blockage of the vasopressin type II receptor over 24 hours in responders with stage D heart failure","volume":"57","author":"Imamura","year":"2016","journal-title":"Int. Heart J."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0075","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/CIRCIMAGING.111.963496","article-title":"Echocardiographic evaluation of hemodynamics in patients with decompensated systolic heart failure","volume":"4","author":"Nagueh","year":"2011","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcha.2018.09.008_bb0080","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/ejechocard\/jer157","article-title":"Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study","volume":"12","author":"Dokainish","year":"2011","journal-title":"Eur. J. Echocardiogr."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jacc.2007.03.048","article-title":"Echocardiography in heart failure: applications, utility, and new horizons","volume":"50","author":"Kirkpatrick","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12947-015-0022-7","article-title":"Echocardiographic characteristics of patients with acute heart failure requiring tolvaptan: a retrospective study","volume":"13","author":"Nakada","year":"2015","journal-title":"Cardiovasc. Ultrasound"},{"key":"10.1016\/j.ijcha.2018.09.008_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0002-9149(84)90034-1","article-title":"Evaluation of size and dynamics of the inferior vena cava as an index of right-sided cardiac function","volume":"53","author":"Moreno","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2012.10.009","article-title":"Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis","volume":"26","author":"Bossone","year":"2013","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1536\/ihj.52.119","article-title":"Prognostic significance of right ventricular dimension on acute decompensation in chronic left-sided heart failure","volume":"52","author":"Maekawa","year":"2011","journal-title":"Int. Heart J."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0115","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0735-1097(93)90097-K","article-title":"Discordance in degree of right and left ventricular dilation in patients with dilated cardiomyopathy: recognition and clinical implications","volume":"21","author":"Lewis","year":"1993","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0120","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0002-9149(97)00780-7","article-title":"Comparison of mortality rates and progression of left ventricular dysfunction in patients with idiopathic dilated cardiomyopathy and dilated versus nondilated right ventricular cavities","volume":"80","author":"Sun","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0125","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12574-017-0330-z","article-title":"Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure","volume":"15","author":"Niwa","year":"2017","journal-title":"J. Echocardiogr."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0130","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial","volume":"52","author":"Udelson","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0135","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0140","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00877324","article-title":"Ischemic right ventricular dysfunction","volume":"8","author":"L\u00f3pez-Send\u00f3n","year":"1994","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0145","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.amjcard.2009.10.020","article-title":"Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure","volume":"105","author":"Testani","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0150","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0033-0620(98)80049-2","article-title":"Ventricular interdependence: significant left ventricular contributions to right ventricular systolic function","volume":"40","author":"Santamore","year":"1998","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0155","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.CIR.71.3.473","article-title":"Contribution of left ventricular contraction to the generation of right ventricular systolic pressure in the human heart","volume":"71","author":"Feneley","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2018.09.008_bb0160","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1152\/ajplegacy.1967.213.3.711","article-title":"Dependence of ventricular distensibility on filling of the opposite ventricle","volume":"213","author":"Taylor","year":"1967","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0165","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcha.2018.09.008_bb0170","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"Hunt","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0175","first-page":"295","article-title":"Right ventricular function and failure: a review","volume":"64","author":"Hines","year":"1991","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.ijcha.2018.09.008_bb0180","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906718301076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906718301076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T22:24:13Z","timestamp":1573683853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906718301076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":36,"alternative-id":["S2352906718301076"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2018.09.008","relation":{},"ISSN":["2352-9067"],"issn-type":[{"type":"print","value":"2352-9067"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2018.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}